Oncopeptides AB , a biotech company focused on difficult-to-treat cancers, today announced that Holger Lembrer, Chief Financial Officer has decided to leave Oncopeptides to pursue a new role in. | June 15, 2023
The shareholders in Oncopeptides AB , reg. no. 556596-6438, with registered office in the municipality of Stockholm, are hereby given notice to attend the Annual General Meeting to be held at. | April 24, 2023
STOCKHOLM, Jan. 18, 2023 /PRNewswire/ Oncopeptides AB (publ.) (NASDAQ Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat
/PRNewswire/ Oncopeptides AB (publ.) (NASDAQ Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for.
/PRNewswire/ Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.